Skip to navigation Skip to content

Acute lymphoblastic leukaemia (ALL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051101

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib for patients with acute lymphoblastic leukaemia (ALL).

ALL and listing dates

ALL is a type of blood cancer.

Listing dates:

  • dasatinib - 1 December 2007
  • imatinib - 1 December 2007
  • ponatinib - 1 November 2015
  • blinatumomab - 1 May 2017
  • inotuzumab ozogamicin - 1 May 2019

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs